• Explore /
  • Poster
  • / A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Abstract Video & Slides Poster

Authors

null

Kiyotaka Yoh

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-Shi, Chiba, Japan

Kiyotaka Yoh , Yasushi Goto , Michael Thomas , Alexander I. Spira , Jacob Sands , Melissa Lynne Johnson , Jonathan Greenberg , Adam Matthew Petrich , Ferdinand M. Guevara , Penny Phillips , Ekaterine Alexandris , Jessie Gu , Yong Zhang , Dale Edward Shuster , Aaron Elliott Lisberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT04656652

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS9127)

DOI

10.1200/JCO.2021.39.15_suppl.TPS9127

Abstract #

TPS9127

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Suresh S. Ramalingam

First Author: Benjamin Besse

First Author: Aurélie Swalduz

First Author: Marina Chiara Garassino